Floatz logo

Mtm-H-001

Immunoglobulin G4-Related Sclerosing Disease

Beijing GoBroad HospitalUNKNOWNN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Immunoglobulin G4-Related Sclerosing Disease cohort.

Asset / SponsorPhaseRating
Leflunomide
Chinese PLA General Hospital
Phase 4BB
Prednisone
Chinese PLA General Hospital
Phase 4BB
Filgotinib
UMC Utrecht
Phase 2CCC
Bcma-Cd19 Ccar T Cells
Peking University People's Hospital
Phase 2CCC
Rituximab
Mayo Clinic
Phase 1CC
Lenalidomide
Mayo Clinic
Phase 1CC
Lvivo-Tavec400 Product
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Early Phase 1NR

Same molecule, other indications

Mtm-H-001 is also rated in:

follicular lymphomaActive
D
Indicative · N/A
30 / 100
View asset →
mantle cell lymphomaActive
D
Indicative · N/A
30 / 100
View asset →
diffuse large B-cell lymphomaActive
D
Indicative · N/A
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →